CGM momentum for T2D
Industry data show growing CGM adoption for type 2 diabetes—Humana reported increased member CGM use from 2021–2023 with coverage expanding into 2026, and Dexcom is presenting full study results at ATTD (March 11–14) that preview long‑term health benefits [] []. Medscape also promoted rtCGM evidence in team‑based T2D care webinars, signalling growing clinical and payer interest [].
Humana’s analysis found CGM use among Medicare Advantage members with insulin-treated T2D rose from fewer than 2 in 100 in January 2021 to about 1 in 6 (~17%) by December 2023 policy.humana.com, and the report noted members who saw an endocrinologist in 2023 were more than four times as likely to be CGM users policy.humana.com; the study is published in the Journal of Managed Care & Specialty Pharmacy. jmcp.org The broader coverage shift behind that uptake traces to the CMS expansion of CGM eligibility on March 2, 2023, which Medicare stakeholders and advocacy groups have cited as a key inflection point for access. diabetes.org Humana’s member materials also specify CGMs and supplies can be obtained through Medicare‑billing DME providers or participating retail pharmacies. assets.humana.com Dexcom’s ATTD briefing and investor release for the March 11–14, 2026 conference describes registry data showing long‑term use of the G7 was associated with weight management and A1c reductions in people with T2D not using insulin, and it scheduled a company symposium on March 12 plus multiple abstracts on one‑year real‑world HbA1c impact. investors.dexcom.com Dexcom also flagged presentations introducing a consensus‑based CGM competency framework for HCPs at the meeting. investors.dexcom.com Medscape has amplified rtCGM evidence through CME and on‑demand activities—running sessions titled “Clinical Conversations on Real‑Time Continuous Glucose Monitoring” (presented at ADA programming and supported by an educational grant) and hosting topical pages summarizing rtCGM data for clinicians. events.diabetes.org Payer and health‑system discussions captured in the AJMC stakeholder series show payers and systems are actively evaluating rtCGM for T2D population‑health programs. ajmc.com
